RxDoctor Payments Data

Brent Bennett, MD

Internal Medicine · Lakeway, TXNPI 1871561035

Payments from drug & device makers

$646in general payments, 2019–2025

Across 35 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$327
  • GSK$212
  • Novo Nordisk$51
  • Johnson & Johnson$28
  • Bausch Health US, LLC$14
  • Lilly USA, LLC$14

What the payments were for

  • Food & beverage$61896%
  • Education$284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen18$327
GSK10$212
Novo Nordisk3$51
Johnson & Johnson2$28
Bausch Health US, LLC1$14
Lilly USA, LLC1$14

How this compares

$646 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$358,953
Medicare patients
1,210
Services billed
5,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide162$190,249
EliquisApixaban89$111,661
JardianceEmpagliflozin82$80,641
Repatha SureclickEvolocumab58$59,142
MounjaroTirzepatide41$48,587
JanuviaSitagliptin Phosphate36$42,176
FarxigaDapagliflozin Propanediol29$38,251
XareltoRivaroxaban31$33,661
MyrbetriqMirabegron48$30,308
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$30,229
ProliaDenosumab13$21,180
SymbicortBudesonide/Formoterol Fumarate33$10,819
Levothyroxine Sodium725$9,479
Rosuvastatin Calcium793$8,550
SynthroidLevothyroxine Sodium120$8,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$51$190,249162 claims
Lilly USA, LLCMounjaro$14$48,58741 claims
GSKTrelegy Ellipta, Anoro Ellipta$212$37,90853 claims
Johnson & JohnsonXarelto$28$33,66131 claims
AmgenProlia$327$21,18013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Lakeway

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →